BOUNDLESS BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BOUNDLESS BIO, INC. (BOLD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-07
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $1.00K, a 75.00% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $31.00K, a 342.86% increase year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $4.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month |
|---|---|---|---|
| 2026-06-30 | $14.00K 10-Q · filed 2026-08-07 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $1.00K derived: sum of 2 quarters · filed 2024-11-07 | $32.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-12 | $32.00K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $31.00K 10-Q · filed 2024-05-13 | ||
| 2023-09-30 | $4.00K 10-Q · filed 2024-11-07 | $8.00K derived: sum of 2 quarters · filed 2024-11-07 | $15.00K 10-Q · filed 2024-11-07 |
| 2023-06-30 | $4.00K 10-Q · filed 2024-08-12 | $11.00K 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $7.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |